Hemostatic Resuscitation

  • N. R. McMullin
  • J. B. Holcomb
  • J. Sondeen
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 2006)


Component therapy is useful for the majority of patients when blood requirements are minimal and there is no associated coagulopathy. Of concern are requirements for massive transfusion and resuscitation that absorb resources and create a short-fall for patients whose injuries are less severe. Additionally, the conventional massive transfusion model of packed RBCs, plasma and platelets actually further dilutes the patient compared to the blood he or she has lost and thus is not the ideal fluid for patients who require this massive transfusion of products. Fresh whole blood has three vital properties: oxygen carrying capacity, volume, and hemostatic effect. In the austere environment of combat the practice of fresh whole blood transfusion has proven beneficial to patients who are coagulopathic and require massive transfusion. Appropriate use following established guidelines can be beneficial and may even be superior to packed RBCs. A fluid containing the vital properties of fresh whole blood would serve as a bridge to allow a patient to be resuscitated without initiating the ‘bloody cycle of death’ that is seen all too often in our current paradigm of massive resuscitation.


Injury Severity Score Hemorrhagic Shock Fresh Freeze Plasma Massive Transfusion Recombinant Factor VIIa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Grosso SM, Keenan JO (2000) Whole blood transfusion for exsanguinating coagulopathy in a US field surgical hospital in postwar Kosovo. J Trauma 49:145–148CrossRefPubMedGoogle Scholar
  2. 2.
    Mabry RL, Holcomb JB, Baker AM, et al (2000) United States Army Rangers in Somalia: an analysis of combat casualties on an urban battlefield. J Trauma 49:515–528CrossRefPubMedGoogle Scholar
  3. 3.
    Repine TB, Perkins J, Kauvar D, Blackborne L (2006) The use of fresh whole blood in massive transfusion. J Trauma (in press)Google Scholar
  4. 4.
    Pearce FJ, Lyons WS (1999) Logistics of parenteral fluids in battlefield resuscitation. Mil Med 164:653–655PubMedGoogle Scholar
  5. 5.
    Kendrick DB (1964) Blood Program in World War II. Office of the Surgeon General, Washington DC, pp 781Google Scholar
  6. 6.
    Mohr R, Martinowitz U, Lavee J, et al (1988) The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations. J Thorac Cardiovasc Surg 96:530–534PubMedGoogle Scholar
  7. 7.
    Manno CS, Hedberg KW, Kim HC, et al (1991) Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 77:930–936PubMedGoogle Scholar
  8. 8.
    Barbee RW, Kline JA, Watts JA (1999) A comparison of resuscitation with packed red blood cells and whole blood following hemorrhagic shock in canines. Shock 12:449–453CrossRefPubMedGoogle Scholar
  9. 9.
    Curtis SE, Cain SM (1992) Regional and systemic oxygen delivery/uptake relations and lactate flux in hyperdynamic, endotoxin-treated dogs. Am Rev Respir Dis 145:348–354PubMedGoogle Scholar
  10. 10.
    Turranoglu S, Kaya S, Kararmaz A, Turhanoglu AD (2001) Lung perfusion in hemorrhagic shock of rats: the effects of resuscitation with whole blood, saline or Hes 6%. Tohoku J Exp Med 195:245–251CrossRefPubMedGoogle Scholar
  11. 11.
    Onen A, Cigdem MK, Deveci E, et al (2003) Effects of whole blood, crystalloid, and colloid resuscitation of hemorrhagic shock on renal damage in rats: an ultrastructural study. J Pediatr Surg 38:1642–1649CrossRefPubMedGoogle Scholar
  12. 12.
    Sondeen JL, Dubick MA, Prince DM, Holcomb JB (2005) Fresh whole blood is the best hypotensive resuscitative fluid in a severe hemorrhage pig model. Circulation (abst, in press)Google Scholar
  13. 13.
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ (1996) The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 334:1685–1690CrossRefPubMedGoogle Scholar
  14. 14.
    Hebert PC, Wells G, Blajchman MA, et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340:409–417CrossRefPubMedGoogle Scholar
  15. 15.
    Malone DL, Dunne J, Tracy JK, et al (2003) Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 54:898–905CrossRefPubMedGoogle Scholar
  16. 16.
    Faringer PD, Mullins RJ, Johnson RL, Trunkey DD (1993) Blood component supplementation during massive transfusion of AS-1 red cells in trauma patients. J Trauma 34:481–485CrossRefPubMedGoogle Scholar
  17. 17.
    Armand R, Hess JR (2003) Treating coagulopathy in trauma patients. Transfus Med Rev 17:223–231CrossRefPubMedGoogle Scholar
  18. 18.
    Angle MK, Faist E (2002) Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit Care 6:298–305CrossRefGoogle Scholar
  19. 19.
    Roumen RM, Hendriks T, van der Ven-Jongekrijg J, et al (1993) Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 218:769–776CrossRefPubMedGoogle Scholar
  20. 20.
    Fransen E, Maessen J, Dentener M, Senden N, Buurman W (1999) Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 116:1233–1239CrossRefPubMedGoogle Scholar
  21. 21.
    Pfaff WW, Fennell RS, HOward RJ, Ireland JF, Scornik JC (1984) Planned random donor blood transfusion in preparation for transplantation. Sensitization and graft survival. Transplantation 38:701–703CrossRefPubMedGoogle Scholar
  22. 22.
    Taylor RW, Manganaro L, O’Brien J, et al (2002) Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med 30:2249–2254CrossRefPubMedGoogle Scholar
  23. 23.
    Bengtsson A, Redl H, Schlag G, Mollnes TE, Hogasen K (1996) Effects on complement activation and cytokine (TNF-alpha and IL-8) release of infusion of anti-TNF-antibodies or a xanthine derivative (HWA 138) in septic baboons. Acta Anaesthesiol Scand 40:244–249CrossRefPubMedGoogle Scholar
  24. 24.
    Landers DF, Dullye KK (1999) Vascular access and fluid resuscitation in trauma. Anesth Clin N Am 17:125–140CrossRefGoogle Scholar
  25. 25.
    Marik PE, Sibbald WJ (1993) Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 269:3024–3029CrossRefPubMedGoogle Scholar
  26. 26.
    Silverman HJ, Tuma P (1992) Gastric tonometry in patients with sepsis. Effects of dobutamine infusions and packed red blood cell transfusions. Chest 102:184–188CrossRefPubMedGoogle Scholar
  27. 27.
    Morisaki H, Sibbald WJ (2004) Tissue oxygen delivery and the microcirculation. Crit Care Clin 20:213–223CrossRefPubMedGoogle Scholar
  28. 28.
    Reiter CD, Wang X, Tanus-Santos JE, et al (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383–1389CrossRefPubMedGoogle Scholar
  29. 29.
    Schechter AN, Gladwin MT (2003) Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 348:1483–1485CrossRefPubMedGoogle Scholar
  30. 30.
    Sloan EP (2003) The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents. Intensive Care Med 29:347–349PubMedGoogle Scholar
  31. 31.
    Moore EE, Johnson JL, Cheng AM, Masuno T, Banerjee A (2005) Insights from studies of blood substitutes in trauma. Shock 24:197–205CrossRefPubMedGoogle Scholar
  32. 32.
    Brohi K, Singh J, Heron M, Coats T (2003) Acute traumatic coagulopathy. J Trauma 54:1127–1130CrossRefPubMedGoogle Scholar
  33. 33.
    Ho AM, Karmakar MK, Dion PW (2005) Are we giving enough coagulation factors during major trauma resuscitation? Am J Surg 190:479–484CrossRefPubMedGoogle Scholar
  34. 34.
    Maclennan S (2006) Risks of fresh frozen plasma (FFP) and platelets. J Trauma (in press)Google Scholar
  35. 35.
    Popovsky MA, Moore SB (1985) Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 25:573–577CrossRefPubMedGoogle Scholar
  36. 36.
    Hoffmeister KM, Felbinger TW, Falet H, et al (2003) The clearance mechanism of chilled blood platelets. Cell 112:87–97CrossRefPubMedGoogle Scholar
  37. 37.
    Engelfriet CP, Reesink HW, Blajchman MA, et al (2000) Bacterial contamination of blood components. Vox Sang 78:59–67CrossRefPubMedGoogle Scholar
  38. 38.
    Blajchman M (2001) Novel platelet products, substitutes and alternatives. Transfus Clin Biol 8:267–271CrossRefPubMedGoogle Scholar
  39. 39.
    Read MS, Reddick RL, Bode AP, et al (1995) Preservation of hemostatic and structural properties of rehydrated lyophilised platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci USA 36:536–542Google Scholar
  40. 40.
    Levi M, Friederich PW, Middleton S, et al (1999) Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 5:107–111CrossRefPubMedGoogle Scholar
  41. 41.
    Davies AR, Judge HM, May JA, Glenn JR, Heptinstall S (2002) Interactions of platelets with Synthocytes, a novel platelet substitute. Platelets 13:197–205PubMedGoogle Scholar
  42. 42.
    Manseth E, Skjervold PO, Fjaera SO, et al (2004) Purification and characterization of Atlantic salmon (Salmo salar) fibrinogen. Comp Biochem Physiol B Biochem Mol Biol 138:169–174CrossRefPubMedGoogle Scholar
  43. 43.
    Kaspereit F, Doerr B, Dickneite G (2004) The effect of fibrinogen concentrate administration on coagulation abnormalities in a rat sepsis model. Blood Coagul Fibrinolysis 15:39–43CrossRefPubMedGoogle Scholar
  44. 44.
    Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879CrossRefPubMedGoogle Scholar
  45. 45.
    Schreiber MA, Holcomb JB, Hedner U, et al (2002) The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 53:252–257CrossRefPubMedGoogle Scholar
  46. 46.
    Sondeen JL, Pusateri AE, Hedner U, Yantis LD, Holcomb JB (2004) Recombinant factor VIIa increases the pressure at which rebleeding occurs in porcine uncontrolled aortic hemorhage model. Shock 22:163–168CrossRefPubMedGoogle Scholar
  47. 47.
    Friederich PW, Henny CP, Messelink EJ, et al (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201–205CrossRefPubMedGoogle Scholar
  48. 48.
    Clark AD, Gordon WC, Walker ID, Tait RC (2004) ‘Last-ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 86:120–124CrossRefPubMedGoogle Scholar
  49. 49.
    Dutton RP, McCunn M, Hyder M, et al (2004) Factor VIIa for correction of traumatic coagulopathy. J Trauma 57:709–718CrossRefPubMedGoogle Scholar
  50. 50.
    Tranholm M, Kristensen K, Kristensen AT, et al (2003) Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 102:3615–3620CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • N. R. McMullin
    • 1
  • J. B. Holcomb
    • 1
  • J. Sondeen
    • 1
  1. 1.United States Army Institute of Surgical ResearchFt. Sam HoustonUSA

Personalised recommendations